title: The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
abstract: BACKGROUND
  Medication interactions account for a significant proportion of overanticoagulation in warfarin users. However, little is known about the incidence or degree of interaction with commonly used oral antibiotics.
  
  
  OBJECTIVE
  To investigate the incidence and degree of overanticoagulation associated with commonly used oral antibiotics.
  
  
  METHODS
  Retrospective cohort study of patients using warfarin who initiated an antibiotic (azithromycin, levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indications between January 1998 and December 2002. The incidence of international normalized ratio (INR) elevation and the degree of change and bleeding events after institution of either medication type was recorded.
  
  
  METHODS
  Patients at a university-affiliated Veteran's Affairs Medical Center.
  
  
  RESULTS
  The mean change in INR was -0.15 for terazosin, 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean INR changes in the antibiotic groups were all statistically different from the terazosin group. The incidence of supratherapeutic INR was 5% for terazosin, 31% for azithromycin, 33% for levofloxacin, and 69% for TMP/SMX. The incidence of absolute INR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for levofloxacin, and 44% for TMP/SMX.
  
  
  CONCLUSIONS
  Among acutely ill outpatients, oral antibiotics (azithromycin, levofloxacin, and TMP/SMX) increase the incidence and degree of overanticoagulation.
authors.affiliation: Department of Medicine, Division of General Internal Medicine, University of Colorado Health Sciences Center, Denver, USA. jeffrey.glasheen@uchsc.edu
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Glasheen
authors.forename: Randolph V
authors.initials: RV
authors.lastname: Fugit
authors.forename: Allan V
authors.initials: AV
authors.lastname: Prochazka
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use; D015331:Cohort Studies; D004347:Drug Interactions; D005260:Female; D006801:Humans; D019934:International Normalized Ratio / Q000592:standards; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D012189:Retrospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D064704:Levofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D017963:Azithromycin; C041226:Terazosin; D015242:Ofloxacin; D011224:Prazosin